Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02869529
  4. Details
NCT02869529 Clinical Trial

Institut Paoli Calmettes Chronic Lymphatic Leukemia Database

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial

Official title:
Institut Paoli Calmettes Chronic Lymphatic Leukemia Database

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02869529
Other study ID # BDD-LLC-IPC
Secondary ID
Status Recruiting
Phase N/A
First received August 11, 2016
Last updated August 16, 2016
Start date January 2006
Est. completion date December 2030

Study information
Verified date August 2016
Source Institut Paoli-Calmettes
Contact Dominique Genre, MD
Phone 0033491223778
Email drci.up@ipc.unicancer.fr
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertés
Study type Observational [Patient Registry]

Clinical Trial Summary

Database of Institut Paoli-Calmettes patients diagnosed with chronic lymphatic leukemia

Recruitment information / eligibility
Status Recruiting
Enrollment 4200
Est. completion date December 2030
Est. primary completion date January 2030
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 95 Years
Eligibility Inclusion Criteria:

- Diagnosis of chronic lymphatic leukemia

Exclusion Criteria:

- Score of Matutes <4

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Other:
• Data collection

Locations
Country Name City State
France Institut Paoli-Calmettes Marseille Bouches-du Rhône

Sponsors (1)
Lead Sponsor Collaborator
Institut Paoli-Calmettes

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Survival of patients Overall survival of all patients who come in the center 10 years No
Secondary Collection of patients characteristics Collection of characteristics of patients treated at Institut Paoli Calmettes in order to set up prospective and retrospective studies 10 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03204188 - Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Phase 2
Terminated NCT00768339 - A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas Phase 1/Phase 2
Completed NCT03289182 - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
Terminated NCT05244070 - A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 1
Completed NCT03720561 - A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
Completed NCT02666898 - Phase II Trial GA101 Inbrutinib B CLL Phase 2
Completed NCT00738829 - Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL Phase 1/Phase 2
Completed NCT03301207 - A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy Phase 1
Completed NCT04290923 - Determination of Blood Tumor Cells
Completed NCT04204057 - Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Phase 2
Recruiting NCT03331198 - Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Phase 1/Phase 2
Completed NCT00545714 - A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) Phase 2
Completed NCT02639910 - Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Phase 2
Completed NCT00220311 - A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Phase 4
Active, not recruiting NCT04540796 - A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Phase 1
Recruiting NCT05650723 - Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab Phase 2
Recruiting NCT06299540 - Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
Recruiting NCT02782351 - Humanized CAR-T Therapy for Treatment of B Cell Malignancy Phase 1/Phase 2
Completed NCT00206726 - Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) Phase 2